XMU-MP-1 weakened the therapeutic effect of LIPUS, and myocardial inflammation in mice was better than that in the PD-1 inhibitor group; therefore, activation of the HIPPO pathway in CD4+ T-cells contributes to LIPUS for improving ICI-related myocarditis. Here, CD4 is linked to myocarditis.